Archimedic Blog

I had the privilege of interviewing the Value Analysis Whisperer himself, Mark Copeland, who cracked open the black box of Value Analysis Committees and shared the secrets that MedTech companies need ...

You’ve probably heard of Proteus.  mAt one time it was the darling of digital health. But within a single year, Proteus went from a $1.5B valuation to a fire sale at $15m. Here's a recreation of event...

Quick 510(k) = Quick exit. Right? Not quite.

Here's some interesting data in the chart below. The data is a bit dated. But the push for the quick 510(k) happens just as much today as it did back when...

 Consider this analogy..  You are driving across the US, planning for a week to travel from coast to coast. With elevated gas prices you want to optimize for fuel consumption.  Without much thought or...

Here are 4 steps on how to clearly define the clinical outcome that compels adoption of your new medical device.

If you are growing a medical device business, a big part of your mission is to impro...

Consider a medical device startup, facing a critical market decision: Should the company go big, aiming for the $1B market out of the gate? Or should the company go small, proving value with an initia...

True story. A medical device manufacturer developed an at-home wearable defibrillator for populations at high risk of sudden cardiac death. This device was intended to be a bridge – worn for approxima...

Clinical use is a significant milestone for most medical device companies. Investors often see this milestone as a significant de-risking activity – one that can come with valuation bumps and subseque...

“You need to show clinical evidence that your medical device provides a benefit.” It's a common request that early medical device innovators hear after they gain regulatory clearance. It’s rational, e...